Advancing Science. Improving Connections.
Next-generation transdermal cannabinoid therapeutics to improve the lives of patients affected by rare and near-rare neuropsychiatric conditions.
Focusing on the unmet medical needs of patients with rare disorders and their families
Progressing our mission to improve the lives of patients battling certain rare and near-rare diseases
Pioneering cannabinoid treatments for neuropsychiatric conditions
Zynerba Pharmaceuticals Added to Russell 2000® and 3000® IndexesRead More
Zynerba Pharmaceuticals Receives New U.S. Patent for Treatment of Autism Spectrum Disorder with CannabidiolRead More
Zynerba Pharmaceuticals to Present at FDA’s Public Hearing on Scientific Data and Information about Products Containing Cannabis or Cannabis-derived CompoundsRead More
Zynerba Pharmaceuticals Announces Initiation of Phase 2 Trial of Zygel™ in 22q11.2 Deletion SyndromeRead More